Profilaggrin, Dry Skin, and Atopic Dermatitis Risk: Size Matters  by McGrath, John A.
commentary
10 Journal of Investigative Dermatology (2012), Volume 132 
been suggested that the number of FLG 
repeats can relate to a dry skin pheno-
type; i.e., fewer repeats may lead to less 
FLG protein expression and drier skin 
(Ginger et al., 2005). What is currently 
not known, however, is whether there is a 
relationship between the intragenic copy 
number variation in FLG and the risk of 
atopic dermatitis.
In this issue, Brown et al. (2012) com-
pare FLG intragenic copy number varia-
tion in a cohort of Irish pediatric atopic 
dermatitis patients and controls. In the 
combined Irish population (~1,800 sub-
jects tested), the 11-monomer repeat 
variant was most common (51.5%), fol-
lowed by the 10-repeat allele (33.9%), 
with the 12-repeat allele being the least 
frequent (14.6%). After common FLG 
mutations were excluded, however, the 
control group was shown to have a high-
er number of repeats than did the cases. 
Moreover, copy number variation was 
shown to correlate with urocanic acid 
levels (derived from FLG proteolysis) in 
the stratum corneum. The findings indi-
cate that copy number variation in the 
FLG gene affects the composition of the 
stratum corneum and makes a significant 
dose-dependent contribution to atopic 
dermatitis risk.
The findings by Brown et al. (2012) 
prompt the question of how FLG intra-
genic copy number variation and atopic 
dermatitis risk compare with the same 
risk associated with FLG gene muta-
tions. To date, loss-of-function mutations 
in FLG represent the strongest and most 
important single genetic factor in the eti-
ology of atopic dermatitis, with an odds 
ratio from meta-analysis estimated to be 
3.12 (Baurecht et al., 2007). In Brown 
and colleagues’ current report, the com-
parable odds ratio for the effect of copy 
number variation is much lower, 1.14. 
Nevertheless, when comparing individu-
als with 10 FLG repeats on both alleles 
with subjects who have 12 repeats on 
both alleles (i.e., 20 vs. 24 FLG polypep-
tides), the increased odds ratio for atopic 
dermatitis in the former is 1.67.
As clinicians are aware, the sever-
ity and behavior of atopic dermatitis 
can vary enormously among individu-
als, and the precise or relative influence 
of intragenic copy number variation in 
FLG on disease parameters such as time 
of disease onset, extent and pattern of 
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Mutations in the FLG gene, which encodes profilaggrin, are known to be a major 
risk factor for atopic dermatitis as well as other atopic diseases and systemic aller-
gies. New research, however, shows that intragenic copy number variation with-
in FLG also represents an independent risk factor for atopic dermatitis. The new 
findings indicate that upregulating fLG protein levels by 5–10% may have clinical 
utility in improving the management of many patients with dry skin and atopy. 
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The major component of keratohya-
lin granules within the granular layer is 
profilaggrin, an ~500-kDa, highly phos-
phorylated, histidine-rich polypeptide 
that is encoded by the FLG gene. During 
posttranslational processing, individual 
filaggrin (FLG) polypeptides, each ~35 
kDa (324 amino acids), is released pro-
teolytically. In the stratum corneum, 
FLG is degraded further to generate 
hygroscopic amino acids that contrib-
ute to skin natural moisturizing factor 
and the formation of an intact skin bar-
rier. The fundamental importance of 
profilaggrin to skin barrier integrity was 
realized in 2006 with the discovery of 
loss-of-function mutations in the FLG 
gene in patients with the semidominant 
condition ichthyosis vulgaris (Smith et 
al., 2006). FLG mutations were then also 
shown to be a major risk factor for atopic 
dermatitis (Palmer et al., 2006). Notably, 
the presence of one FLG mutation has 
been found to increase the risk of atopic 
dermatitis 6-fold, and two mutations 
increase the risk 150-fold. FLG muta-
tions have also been associated with 
increased susceptibility to atopic asth-
ma, the atopic march, systemic allergies, 
contact dermatitis, and peanut allergy 
(Marenholz et al., 2006; Weidinger et 
al., 2006; Palmer et al., 2007; Brown et 
al., 2011; Carlsen et al., 2011).
The significance of FLG in the patho-
physiology of atopic dermatitis has also 
been suggested in cases lacking specific 
mutations in the FLG gene. Notably, 
skin inflammation in atopic dermatitis 
is associated typically with increased 
expression of cytokines, such as IL-4 and 
-13, both of which have been shown to 
reduce FLG gene and protein expression 
in keratinocytes (Howell et al., 2007). 
The cytokine IL-22 has also been shown 
to reduce FLG expression (Gutowska-
Owsiak et al., 2011). Moreover, polymor-
phisms in the genes encoding IL-10 and 
-13 can affect FLG expression (Lesiak et 
al., 2011). Reduced FLG levels, either 
from a primary gene mutation or from a 
secondary reduction in protein expres-
sion, can also influence innate immune 
responses via Toll-like-receptor stimuli 
and thus contribute to skin inflammation 
(Lee et al., 2011).
Consequently, although mutations in 
the FLG gene represent the most signifi-
cant genetic risk factor for atopic derma-
titis identified thus far, it is evident that 
FLG gene and protein expression can be 
influenced by several other factors.
In addition to mutations, the FLG 
gene demonstrates intragenic copy num-
ber variation. FLG encodes 10 highly 
homologous and only slightly genetically 
different FLG units, but the exact num-
ber encoded can vary, with individuals 
harboring 10, 11, or 12 monomers. The 
differences are attributable to possible 
repeats of subunits 8 or 10 or both. It has 
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dermatitis, optimal emollient use, and 
response (or lack thereof) to topical 
therapies remains to be seen. However, 
Brown et al. (2012) identify an impor-
tant therapeutic consideration, namely, 
that a 5–10% increase in FLG in the skin 
could be clinically useful. Current work 
to identify drugs, small molecules, and 
compounds with the capacity to upregu-
late FLG expression is therefore expected 
to be of considerable value in improv-
ing the management of atopic dermatitis 
and other skin and systemic disorders in 
which a primary or secondary reduction 
in FLG expression contributes to disease 
pathophysiology.
In pursuit of this therapeutic target, 
a number of compounds have already 
been shown to increase FLG expression 
in keratinocytes. For example, oleanolic 
acid and ursolic acid—pentacyclic tri-
terpenoids that occur naturally in many 
medicinal herbs and plants—have both 
been shown to improve skin barrier func-
tion by increasing FLG expression (Lin et 
al., 2007), and many more compounds 
with similar, or perhaps superior, FLG-
promoting properties are likely to be 
discovered soon. A therapeutic future 
that can be extrapolated from the report 
by Brown et al. (2012) is one in which 
increasing FLG expression in individuals 
with lower intragenic copy number FLG 
allele variants has the potential to improve 
skin barrier integrity and reduce disease 
burden for several disorders. There is a 
clear translational route to follow, one 
that is likely to have huge clinical impact 
in the not too distant future. Size, when 
it comes to FLG intragenic copy number 
variation, really does matter.
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Dermatology Life Quality Index: Time 
to Move forward
Tamar Nijsten1
Since its introduction in 1994, the Dermatology Life Questionnaire Index (DLQI) 
has played an important role in assessing dermatology-specific health-related 
quality of life (HRQoL) and has affected several medical decision-making pro-
cesses. However, the psychometric requirements for instruments have evolved 
over the years, and the DQLI is failing these new standards. Therefore, it is time 
to move forward and use valuable alternatives because the DLQI’s scientific lim-
itations outweigh the practicalities of its use.
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The Dermatology Life Questionnaire 
Index (DLQI) (Finlay and Kahn, 
1994), the first dermatology-specific 
health-related quality-of-life (HRQoL) 
instrument, has helped enormously 
to introduce and assess HRQoL in 
dermatology. Studies have shown that 
the DLQI captures specific informa-
tion that is missed by generic HRQoL 
instruments such as the SF-36, illustrat-
ing the need for dermatology-specific 
questionnaires. Although the DLQI was 
|A 5–10% increase in filaggrin may be clinically useful.
